Series A · Biotech & Pharma

Series A Biotech pitch decks built around the path to the clinic.

Series A biotech rounds typically fund a lead program into or through early clinical development. The deck must present the IND path and trial design as a deliberate strategy, show the pipeline behind the lead, and tie capital to clinical readouts that create the next step-up in value.

At a glance

Typical deck length
15–20 slides plus appendix
Who you're pitching
Series A lead investors, multi-stage VCs, and sector specialists writing $3–15M checks.
Lead with
IND-enabling package status · Phase 1 design and endpoints · Pipeline milestone map
Trusted by founders & teams at
PfizerSonyBayerMerckUPMCFarmers InsurancePella
What investors need to believe

What Series A Biotech investors need to believe.

A Biotech round at Series A turns on a handful of beliefs. Your deck should build each one before a partner has to ask.

The IND package is solid

Preclinical efficacy, safety and CMC readiness support a credible clinical entry.

The trial design answers the right question

Endpoints, population and design produce a readout investors will value.

There's more than one shot on goal

Follow-on programs or indications extend the opportunity beyond the lead asset.

The capital reaches a readout

The raise funds the company to a clinical data point, with buffer.

Metrics & proof

What to lead with at Series A.

At this stage, these are the numbers and evidence that carry the room. Each one should tie out to your model and data room.

IND-enabling package status

Show what's complete, in progress and remaining, with dates.

Phase 1 design and endpoints

Summarize population, endpoints and any early efficacy signals sought.

Pipeline milestone map

Plot programs against readouts on a single timeline.

Runway to readout

Show cash through the key clinical data point plus contingency.

Comparable transactions

Ground the opportunity in relevant partnership or acquisition precedent.

Recommended slide order

How to structure a Series A Biotech deck.

A 15–20 slides plus appendix structure tuned for this round. Tap any slide for the full guide.

  1. Title Slide

    At Series A, position the company as a category rather than a feature; the one-liner should read like the opening of a market-leading story.

  2. Traction Slide

    In biotech, traction is data: present key results, regulatory interactions and milestones achieved.

    Biotech-specific
  3. Problem Slide

    At Series A, frame the problem as a market-level pain with a clear economic cost, validated by a growing base of paying customers.

  4. Solution Slide

    At Series A, the solution should read as a repeatable product, with proof that the outcome holds across a growing set of customers.

  5. Market Size Slide

    Size by addressable patient population and pricing precedent, then show expansion indications.

    Biotech-specific
  6. Product Slide

    At Series A, the product slide should demonstrate maturity and depth — the core workflow plus the capabilities that drive retention and expansion.

  7. Business Model Slide

    At Series A, investors expect early unit economics — contribution margin, CAC payback and retention that show the model can scale profitably.

  8. Go-to-Market Slide

    At Series A, the go-to-market slide should prove repeatability: a defined motion, predictable pipeline and acquisition economics that justify scaling the team.

  9. Competition Slide

    At Series A, demonstrate a durable advantage forming: win rates, retention against competitors, or data and network effects that strengthen with scale.

  10. Team Slide

    At Series A, investors look for the leadership layer forming — functional leaders in sales, engineering or operations who can scale their teams.

  11. Financials Slide

    At Series A, investors expect a driver-based model with real unit economics, a credible growth plan and a clear view of burn and efficiency.

  12. The Ask & Use of Funds Slide

    Show the capital needed to reach the clinical readout and what that readout unlocks.

    Biotech-specific
Objections to pre-empt

What Biotech investors will push on at Series A.

What if Phase 1 shows a safety signal?

How the deck answers it: Show the safety margin from preclinical work and the dose-escalation plan designed to manage it.

Is CMC going to delay the program?

How the deck answers it: Address manufacturing readiness, vendors and timelines directly.

How does this become a partnership or exit?

How the deck answers it: Use comparable deals and strategic interest to show what value looks like after the readout.

What founders say

Trusted by founders. Backed by results.

They were able to give us insight into a comprehensive and emerging landscape. They provided further resources with case studies and data to make our arguments more compelling; while being timely and communicative. They're an asset to any team moving forward.
John McTernan
Sr. Director of Strategy | Pfizer
[They] were educated in the biopharma space and was able to give us insight into the landscape. They provided further resources/data to make our arguments more compelling. He was timely and communicative. An asset to any team moving forward.
Zander Ford
Founder | Conscious Founders
(For our acquisition of Modular Water), they really built the case with deep research. Highly professional. They took the time to work through a number of iterations of the project and maintained outstanding communication. Highly recommend.
Riggs Eckleberry
CEO | OriginClear HoldCo.
FAQ

Common questions. Clear answers.

What do Series A biotech investors look for?
A strong preclinical package, a credible path into the clinic, a thoughtful trial design, IP protection and a team that can execute — plus enough capital to reach a meaningful data readout.
How should a Series A biotech deck present the pipeline?
As a milestone map: each program against its next value-inflection point and expected data readout, so investors see the de-risking sequence at a glance.
What does a custom engagement cost?
We're upfront about pricing: custom presentations start at $25K, and monthly packages are $15,000 — which include a team lead, researcher, analyst, and investor-relations expert for the price of one employee.
How fast can you turn it around?
Typical turnaround is 8–10 business days from the strategy session to final delivery. Expedited timelines are available when your raise is on a clock.
Free deck audit

Raising your Series A round? Get the deck right first.

Drop your details and we'll send a free deck audit — then jump on a 15-minute intro call to walk through exactly what to fix before you pitch.

  • We reply within 24 hours
  • Complete founder confidentiality
Prefer to talk first? Book a 1:1 intro call
Get your free deck audit